Background: The aim of this study was to determine the biochemical recurrence among Black and White American men with grade group 2-5 prostate cancer managed primarily by radical prostatectomy (RP).

Methods: This was a single-institution, retrospective study evaluating biochemical recurrence by self-identified race. 163 patients who underwent RP at the University Hospitals Cleveland Medical Center between 2015-2021 were analyzed for racial differences in age at diagnosis, clinical stage, and preoperative serum prostate-specific antigen (PSA). Patients were followed for PSA recurrence (PSA ≥ 0.2 ng/ml). Multivariate analysis was used to determine clinical and pathologic variables that were significant in predicting biochemical recurrence after RP and to determine whether race was an independent predictor of biochemical recurrence-free survival (BCRFS).

Results: Of 163 patients, 82 (50.3%) were Black Americans and 81 (49.7%) were White Americans with a median age of 62.7 ranging between 38.7 to 76.3 years. The grade-specific distribution of cancer 3+4 was 54.9% 65.4%; 4+3 was 25.6% 30.9%; 4+4 was 7.3% 2.5%; 4+5 was 12.2% 1.2% in Black American and White American men. Univariate analysis of BCRFS using Kaplan-Meier method demonstrated a significant difference among levels of Gleason score between Black Americans and White Americans (P = 0.041). Multivariable analysis after controlling the effects of age, Gleason score exhibited no significant difference of BCRFS comparing Black and White American men (P = 0.145). Specifically, the hazard of biochemical recurrence among Black Americans was 1.6 times (95% CI: 0.85-3.02) compared to White Americans (P = 0.145).

Conclusion: Our study demonstrated a significant difference in BCRFS between Black and White American patients. Additional studies with larger sample size underlying this clinical disparity are warranted.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428572PMC

Publication Analysis

Top Keywords

biochemical recurrence
20
white american
16
black white
12
american men
12
black americans
12
white americans
12
prostate cancer
8
recurrence black
8
163 patients
8
demonstrated difference
8

Similar Publications

: Prostate cancer is one of the most commonly diagnosed cancers in the male population and the fifth leading cause of cancer death worldwide in men as of 2022. One of the potential biomarkers that can predict the progression of the disease is the transmembrane adhesion molecule CD44s. The aims of this study were to determine the expression of CD44s in prostate cancer in the central tumor mass and in the tumor periphery of the disease and to compare it with the clinicopathological parameters (PSA, Gleason score, surgical margins, and biochemical recurrence of the disease) in patients treated with radical prostatectomy.

View Article and Find Full Text PDF

Higher intraoperative opioid doses may be associated with worse long-term oncological outcomes after radical prostatectomy (RP) for prostate cancer. We aimed to evaluate the impact of higher doses of intraoperative opioids and type of anesthesia on biochemical recurrence (BCR) and mortality after RP in a high-volume tertiary center. All patients underwent RP at our center between 2015 and 2021.

View Article and Find Full Text PDF

Glycosylphosphatidylinositol (GPI) biosynthesis defect 11 (GPIBD11), part of the heterogeneous group of congenital disorders of glycosylation, is caused by biallelic pathogenic variants in . This rare disorder has previously been described in only 12 patients. We report four novel patients: two sib fetuses with congenital anomalies affecting several organs, including the heart; a living girl with tetralogy of Fallot, global developmental delay, behavioral abnormalities, and atypic electroencephalography (EEG) without epilepsy; a girl with early-onset, treatment-resistant seizures, developmental regression, and recurrent infections, that ultimately passed away prematurely due to pneumonia.

View Article and Find Full Text PDF

Over the past decade, prostate-specific membrane antigen positron emission tomography (PSMA-PET) has revolutionized prostate cancer (PCa) imaging, offering greater sensitivity and specificity compared to conventional imaging modalities such as CT, MRI, and bone scintigraphy. PSMA-PET is particularly valuable in staging newly diagnosed patients with intermediate- and high-risk disease, detecting biochemical recurrence, and evaluating metastatic cases. By utilizing radiotracers that accumulate specifically in PSMA-expressing cells, even small metastases can be detected, offering a detailed assessment of cancer extent and enabling more targeted diagnostic evaluations.

View Article and Find Full Text PDF

Objective: To perform a systematic review and meta-analysis to assess the relationship between intraprostatic maximum standardised uptake value (SUV) of the dominant prostatic lesion as measured on preoperative prostate-specific membrane antigen (PSMA) positron emission tomography (PET) with radical prostatectomy International Society of Urological Pathology (ISUP) Grade Group, pathological tumour (pT) staging, and biochemical recurrence (BCR).

Methods: Prostate-specific membrane antigen PET may offer non-invasive assessment of histopathological and oncological outcomes before definitive treatment. SUV of the dominant lesion has been explored as a prognostic biomarker.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!